Regen BioPharma Inc (RGBP)

[29YEARINVESTOR]

Wrong! Have a look look at the RGBP Dream team.
Harry Lander and KOO’s go way back he use to be RGBP President! Now a business partner through Dyo-Bio!

Regen has filed an Investigational New Drug Application (IND#16928) for their drug termed tCellVax with the U.S. FDA. tCellVax is intended to utilize siRNA to silence NR2F6 activity in human immune cells thereby activating these immune cells in such a way that they can attack cancer cells. The Company believes that adding new intellectual property utilizing modified mRNA will profoundly simplify the drug development process and thus speed development.

Dyo Biotechnologies has been contracted to assist Regen with the development of the above mentioned technology.

A blast from the past that has now come back around as team Dyo-Bio!
Regen BioPharma, Inc., (OTCBB: RGBP, OTC: RGBP) announced the appointment of Harry Lander, PhD as its new president. Dr. Lander will work closely with the Company's Chairman & CEO David Koos as Regen BioPharma prepares to take the next steps forward in small molecule and immuno-oncological therapeutics.

Time to get up to date! I’ve done my DD!
LoL! there is a lot of Fud and misinformation going around about RGBP that can be easily be proven Wrong!
Want to know the facts do the search!
Email or call KOO’s he likes return Email addresses

REGEN BIOPHARMA, INC.
4700 Spring Street, Suite 304
La Mesa, CA 91942
U.S.A.

Telephone: [phone] ext: 800
Fax: [phone]
Email: [e-mail]

Check Out RGBP Dream team on our teams new active site!

It’s easy to find current active Dyo bio sites with a simple search!
RGBP’s active new Dyo-Bio Dream Team:
Active current sites!

https://www.datanyze.com/companies/dyo-bio-technologies/473660573

Dyo-bio Operating Status active
https://www.crunchbase.com/organization/dyo-biotechnologies
Revenue
$5 M
Employees
26

https://www.linkedin.com/in/harry-lander-5a82b610b

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168267352


Submitted 15 Mar 2022 Preclinical trials in Myelodysplastic syndromes in USA (IV) (Regen Biopharma pipeline)
10 Mar 2022 Preclinical development in Breast cancer and Myelodysplastic syndrome is ongoing USA